Liquidia Corp (LQDA)

$7.185

+0.28

(+4.13%)▲

Market is closed - opens 8 PM, 07 Dec 2023

Insights on Liquidia Corp

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 4.78M → 3.67M (in $), with an average decrease of 23.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -23.51M → -15.79M (in $), with an average increase of 48.9% per quarter

  • Vs SGEN

    In the last 1 year, Seagen, Inc. has given 83.0% return, outperforming this stock by 55.7%

Performance

  • $6.85
    $7.41
    $7.19
    downward going graph

    4.73%

    Downside

    Day's Volatility :7.49%

    Upside

    2.9%

    downward going graph
  • $5.06
    $9.95
    $7.19
    downward going graph

    29.62%

    Downside

    52 Weeks Volatility :49.15%

    Upside

    27.74%

    downward going graph

Returns

PeriodLiquidia CorpSector (Health Care)Index (Russel 2000)
3 Months
0.73%
0.3%
0.0%
6 Months
-19.67%
1.7%
0.0%
1 Year
27.31%
-4.0%
-2.4%
3 Years
46.81%
17.2%
-6.5%

Highlights

Market Capitalization
471.9M
Book Value
$0.74
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.88
Wall Street Target Price
15.83
Profit Margin
0.0%
Operating Margin TTM
-404.87%
Return On Assets TTM
-27.36%
Return On Equity TTM
-80.52%
Revenue TTM
18.3M
Revenue Per Share TTM
0.28
Quarterly Revenue Growth YOY
16.2%
Gross Profit TTM
13.1M
EBITDA
-51.9M
Diluted Eps TTM
-0.88
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.03
EPS Estimate Next Year
-1.16
EPS Estimate Current Quarter
-0.21
EPS Estimate Next Quarter
-0.22

Analyst Recommendation

Buy
    84%Buy
    7%Hold
    7%Sell
Based on 13 Wall street analysts offering stock ratings for Liquidia Corp(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 120.32%

Current $7.19
Target $15.83

Company Financials

FY17Y/Y Change
Revenue
7.3M
↓ 45.08%
Net Income
-29.2M
↑ 82.97%
Net Profit Margin
-401.68%
↓ 281.12%
FY18Y/Y Change
Revenue
2.7M
↓ 62.7%
Net Income
-53.1M
↑ 82.26%
Net Profit Margin
-2.0K%
↓ 1561.24%
FY19Y/Y Change
Revenue
8.1M
↑ 198.2%
Net Income
-46.4M
↓ 12.7%
Net Profit Margin
-574.69%
↑ 1388.23%
FY20Y/Y Change
Revenue
739.6K
↓ 90.84%
Net Income
-57.5M
↑ 23.93%
Net Profit Margin
-7.8K%
↓ 7198.3%
FY21Y/Y Change
Revenue
12.9M
↑ 1637.81%
Net Income
-29.8M
↓ 48.2%
Net Profit Margin
-231.7%
↑ 7541.29%
FY22Y/Y Change
Revenue
15.9M
↑ 23.98%
Net Income
-38.4M
↑ 28.82%
Net Profit Margin
-240.76%
↓ 9.06%
Q2 FY22Q/Q Change
Revenue
3.9M
↑ 12.2%
Net Income
-9.9M
↓ 41.42%
Net Profit Margin
-253.29%
↑ 231.82%
Q3 FY22Q/Q Change
Revenue
3.2M
↓ 19.22%
Net Income
-9.4M
↓ 5.75%
Net Profit Margin
-295.51%
↓ 42.22%
Q4 FY22Q/Q Change
Revenue
5.4M
↑ 69.35%
Net Income
-6.0M
↓ 36.2%
Net Profit Margin
-111.32%
↑ 184.19%
Q1 FY23Q/Q Change
Revenue
4.5M
↓ 16.18%
Net Income
-13.1M
↑ 120.11%
Net Profit Margin
-292.32%
↓ 181.0%
Q2 FY23Q/Q Change
Revenue
4.8M
↑ 6.52%
Net Income
-23.5M
↑ 79.05%
Net Profit Margin
-491.37%
↓ 199.05%
Q3 FY23Q/Q Change
Revenue
3.7M
↓ 23.15%
Net Income
-15.8M
↓ 32.86%
Net Profit Margin
-429.31%
↑ 62.06%
FY17Y/Y Change
Total Assets
14.8M
↑ 74.91%
Total Liabilities
48.5M
↑ 81.57%
FY18Y/Y Change
Total Assets
49.4M
↑ 232.93%
Total Liabilities
30.7M
↓ 36.68%
FY19Y/Y Change
Total Assets
68.8M
↑ 39.3%
Total Liabilities
33.9M
↑ 10.3%
FY20Y/Y Change
Total Assets
99.5M
↑ 44.58%
Total Liabilities
28.4M
↓ 16.08%
FY21Y/Y Change
Total Assets
93.7M
↓ 5.83%
Total Liabilities
28.5M
↑ 0.06%
FY22Y/Y Change
Total Assets
129.2M
↑ 37.84%
Total Liabilities
38.8M
↑ 36.23%
Q2 FY22Q/Q Change
Total Assets
139.1M
↑ 48.71%
Total Liabilities
37.0M
↓ 3.04%
Q3 FY22Q/Q Change
Total Assets
132.6M
↓ 4.68%
Total Liabilities
37.5M
↑ 1.51%
Q4 FY22Q/Q Change
Total Assets
129.2M
↓ 2.54%
Total Liabilities
38.8M
↑ 3.31%
Q1 FY23Q/Q Change
Total Assets
128.9M
↓ 0.21%
Total Liabilities
47.3M
↑ 21.93%
Q2 FY23Q/Q Change
Total Assets
121.6M
↓ 5.68%
Total Liabilities
60.9M
↑ 28.89%
Q3 FY23Q/Q Change
Total Assets
111.6M
↓ 8.19%
Total Liabilities
63.6M
↑ 4.42%
FY17Y/Y Change
Operating Cash Flow
-24.3M
↑ 74.17%
Investing Cash Flow
-2.5M
↓ 11.82%
Financing Cash Flow
28.8M
↑ 371.63%
FY18Y/Y Change
Operating Cash Flow
-31.8M
↑ 31.04%
Investing Cash Flow
-870.9K
↓ 65.77%
Financing Cash Flow
68.8M
↑ 138.83%
FY19Y/Y Change
Operating Cash Flow
-48.3M
↑ 51.69%
Investing Cash Flow
-1.9M
↑ 112.42%
Financing Cash Flow
66.4M
↓ 3.52%
FY20Y/Y Change
Operating Cash Flow
-54.1M
↑ 12.14%
Investing Cash Flow
247.9K
↓ 113.4%
Financing Cash Flow
63.4M
↓ 4.48%
FY21Y/Y Change
Operating Cash Flow
-34.0M
↓ 37.14%
Investing Cash Flow
-107.2K
↓ 143.25%
Financing Cash Flow
26.3M
↓ 58.5%
FY22Y/Y Change
Operating Cash Flow
-28.6M
↓ 16.01%
Investing Cash Flow
-587.0K
↑ 447.47%
Financing Cash Flow
65.0M
↑ 146.82%
Q2 FY22Q/Q Change
Operating Cash Flow
-8.4M
↓ 13.83%
Investing Cash Flow
-2.0K
↑ 0.0%
Financing Cash Flow
54.5M
↑ 440.34%
Q3 FY22Q/Q Change
Operating Cash Flow
-5.8M
↓ 31.5%
Investing Cash Flow
-94.0K
↑ 4600.0%
Financing Cash Flow
348.0K
↓ 99.36%
Q4 FY22Q/Q Change
Operating Cash Flow
-4.6M
↓ 20.28%
Investing Cash Flow
-491.0K
↑ 422.34%
Financing Cash Flow
57.0K
↓ 83.62%
Q1 FY23Q/Q Change
Operating Cash Flow
-8.5M
↑ 83.73%
Investing Cash Flow
-243.0K
↓ 50.51%
Financing Cash Flow
10.0M
↑ 17356.14%
Q2 FY23Q/Q Change
Operating Cash Flow
-5.6M
↓ 34.21%
Investing Cash Flow
-243.0K
↑ 0.0%
Financing Cash Flow
-409.0K
↓ 104.11%

Technicals Summary

Sell

Neutral

Buy

Liquidia Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Liquidia Corp
Liquidia Corp
5.18%
-19.67%
27.31%
46.81%
46.81%
Moderna, Inc.
Moderna, Inc.
8.62%
-38.31%
-54.89%
-50.93%
320.86%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-1.38%
9.73%
9.82%
65.7%
115.07%
Novo Nordisk A/s
Novo Nordisk A/s
-1.43%
23.95%
58.41%
192.13%
336.59%
Seagen, Inc.
Seagen, Inc.
0.74%
10.42%
83.05%
20.41%
247.89%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-8.19%
7.19%
13.58%
55.97%
97.18%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Liquidia Corp
Liquidia Corp
NA
NA
NA
-1.03
-0.81
-0.27
0.0
0.74
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.72
-0.22
-0.07
0.0
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
23.18
23.18
1.75
42.5
0.17
0.09
0.01
234.47
Novo Nordisk A/s
Novo Nordisk A/s
41.18
41.18
4.02
2.67
0.89
0.22
0.01
20.77
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-4.16
-0.28
-0.13
0.03
13.52
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.38
26.38
0.5
15.04
0.23
0.14
0.0
64.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Liquidia Corp
Liquidia Corp
Buy
$471.9M
46.81%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$30.4B
320.86%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$88.5B
115.07%
23.18
30.47%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$459.0B
336.59%
41.18
35.11%
Seagen, Inc.
Seagen, Inc.
Hold
$40.2B
247.89%
NA
-32.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.5B
97.18%
26.38
35.94%

Institutional Holdings

  • Caligan Partners LP

    14.24%

  • BlackRock Inc

    5.09%

  • Vanguard Group Inc

    4.27%

  • Kynam Capital Management, LP

    3.08%

  • Eversept Partners, LLC

    2.15%

  • State Street Corporation

    1.62%

Company Information

liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.

Organization
Liquidia Corp
Employees
63
CEO
Dr. Roger A. Jeffs Ph.D.
Industry
Health Technology

Discover More

FAQs